Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 7Phase 1/2 4Phase 3 3Phase 2/3 1

Status

Completed 48Terminated 22Recruiting 18Active not recruiting 15Withdrawn 7Unknown 4Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2

Conditions

Uveal Melanoma 1Rectal Neoplasms 1Melanoma 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 28Cisplatin 28Carboplatin 27Capecitabine 27camrelizumab 25Nivolumab 24apatinib 23Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 19Drug Therapy 18Immunotherapy, Adoptive 17pembrolizumab 16Docetaxel 16Bevacizumab 16Dexamethasone 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12Fluorouracil 11130-nm albumin-bound paclitaxel 11anlotinib 10Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Ipilimumab × Clear all
NCT03682276 2022-12-13

PRIME-HCC

Imperial College London

Phase 1/2 Unknown
32 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03161756 2022-04-07

CHARLI

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Unknown
72 enrolled
Dermatologic

Melanoma

NCT02948348 2021-09-16

Study to Nivolumab Following Preoperative Chemoradiotherapy

National Cancer Center Hospital East

Phase 1/2 Unknown
90 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02913417 2021-04-19

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

California Pacific Medical Center Research Institute

Phase 1/2 Unknown
26 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡